文献速递系统性红斑狼疮其他结缔组织病

SLICC起始队列660例中重度不依从羟氯喹与系统性红斑狼疮复发、损伤及死亡率的关联

Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort.
PubMed 文献 · Arthritis Rheumatol · 2023-11-13

基于SLICC国际多中心起始队列中660例入组时已处方羟氯喹至少3个月的患者,用血清羟氯喹水平客观判定重度不依从,分析其与5年随访期间SLE复发、损伤及死亡率的关联。结果显示重度不依从与次年复发(OR 3.38,95%CI 1.80-6.42)、前3年SDI增加(3年时HR 1.92,95%CI 1.05-3.50)及5年死亡(粗HR 5.41,95%CI 1.43-20.39)独立相关。

要点

  • 660例中48例(7.3%)存在重度羟氯喹不依从,未发现与重度不依从明确相关的协变量。
  • 重度不依从与次年SLE复发独立相关(OR 3.38,95%CI 1.80-6.42)。
  • 重度不依从与前3年SDI增加(3年时HR 1.92,95%CI 1.05-3.50)及5年死亡(粗HR 5.41,95%CI 1.43-20.39)相关。

核心结论

  • 重度不依从与次年SLE复发、早期损伤及5年死亡率独立相关。

研究设计与样本

  • SLICC起始队列为覆盖11个国家33个中心的国际多中心研究。
  • 纳入1849例队列参与者中入组时已处方羟氯喹至少3个月的660例患者(88%为女性),分析其血清。
  • 重度不依从不依从定义为羟氯喹剂量400 mg/日时血清羟氯喹水平<106 ng/mL,或200 mg/日时<53 ng/mL。
  • 复发定义为SLE疾病活动指数2000增加≥4分、开始泼尼松或免疫抑制药物或新发肾脏受累,采用逻辑回归分析其与复发的关联。
  • 损伤(首次SLICC/美国风湿病学会损伤指数[SDI]增加≥1分)和死亡率分别采用Cox比例风险模型分析。

主要发现

  • 血清羟氯喹中位数(四分位距)为388 ng/mL(244-566),48例(7.3%)存在重度羟氯喹不依从。
  • 未发现与重度不依从明确相关的协变量。
  • 重度不依从与复发独立相关(OR 3.38,95%CI 1.80-6.42)。
  • 重度不依从与前3年各年内SDI增加相关(3年时HR 1.92,95%CI 1.05-3.50)。
  • 5年内11例患者死亡,其中3例存在重度不依从(粗HR 5.41,95%CI 1.43-20.39)。

关键数值与推荐

  • 重度不依从判定标准:羟氯喹400 mg/日时血清水平<106 ng/mL,或200 mg/日时<53 ng/mL。
  • 复发定义:SLE疾病活动指数2000增加≥4分、开始泼尼松或免疫抑制药物或新发肾脏受累。
  • 损伤定义:首次SDI增加≥1分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates over five years of follow-up. METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort is an international multicenter initiative (33 centers throughout 11 countries). The serum of patients prescribed HCQ for at least three months at enrollment were analyzed. Severe nonadherence was defined by a serum HCQ level <106 ng/mL or <53 ng/mL for HCQ doses of 400 or 200 mg/day, respectively. Associations with the risk of a flare (defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 increase ≥4 points, initiation of prednisone or immunosuppressive drugs, or new renal involvement) were studied with logistic regression, and associations with damage (first SLICC/American College of Rheumatology Damage Index [SDI] increase ≥1 point) and mortality with separate Cox proportional hazard models. RESULTS: Of the 1,849 cohort participants, 660 patients (88% women) were included. Median (interquartile range) serum HCQ was 388 ng/mL (244-566); 48 patients (7.3%) had severe HCQ nonadherence. No covariates were clearly associated with severe nonadherence, which was, however, independently associated with both flare (odds ratio 3.38; 95% confidence interval [CI] 1.80-6.42) and an increase in the SDI within each of the first three years (hazard ratio [HR] 1.92 at three years; 95% CI 1.05-3.50). Eleven patients died within five years, including 3 with severe nonadherence (crude HR 5.41; 95% CI 1.43-20.39). CONCLUSION: Severe nonadherence was independently associated with the risks of an SLE flare in the following year, early damage, and five-year mortality.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Nguyen Y, Blanchet B, Urowitz MB, et al. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort. Arthritis Rheumatol. 2023. PMID: 37459273. doi:10.1002/art.42645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。